Press Releases

Ascentage Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD and HONG KONG, CHINA /PRNewswire/ – Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer, will present a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, Read More ›

Ascentage Pharma Announces Formation of Clinical Advisory Board

ROCKVILLE, Md. and HONG KONG /PRNewswire/ – Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the formation of a Clinical Advisory Board (CAB) to provide strategic guidance to the Company as it advances its pipeline of novel, apoptosis-targeted therapies and next-generation tyrosine kinase inhibitors. The newly formed board Read More ›

Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers

ROCKVILLE, MARYLAND | Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for APG-1387, a novel small molecule IAP inhibitor for the treatment of advanced solid tumors and hematologic malignancies. Inhibitors of apoptosis (IAPs) Read More ›